NASDAQ:ACRX AcelRx Pharmaceuticals - ACRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AcelRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.63 -0.03 (-4.55%) (As of 03/20/2023 09:40 AM ET) Add Compare Share Share Today's Range$0.61▼$0.6750-Day Range$0.66▼$2.5952-Week Range$0.61▼$7.60Volume42,712 shsAverage Volume211,060 shsMarket Capitalization$4.69 millionP/E Ratio0.10Dividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability AcelRx Pharmaceuticals MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish8.30% of Float Sold ShortDividend StrengthN/ASustainability-2.41Upright™ Environmental ScoreNews Sentiment0.47Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.49 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for AcelRx Pharmaceuticals. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.30% of the float of AcelRx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcelRx Pharmaceuticals has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in AcelRx Pharmaceuticals has recently increased by 7.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcelRx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcelRx Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAcelRx Pharmaceuticals has received a 53.29% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Sufentanil" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for AcelRx Pharmaceuticals is -2.41. Previous Next 3.0 News and Social Media Coverage News SentimentAcelRx Pharmaceuticals has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for AcelRx Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 3 people have searched for ACRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added AcelRx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AcelRx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.60% of the stock of AcelRx Pharmaceuticals is held by insiders. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of AcelRx Pharmaceuticals is 0.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.25.Price to Earnings Ratio vs. SectorThe P/E ratio of AcelRx Pharmaceuticals is 0.11, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.57. Previous Next See Top Rated MarketRank™ Stocks Here About AcelRx Pharmaceuticals (NASDAQ:ACRX) StockAcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.Read More Receive ACRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRX Stock News HeadlinesMarch 18, 2023 | americanbankingnews.comAcelRx Pharmaceuticals (NASDAQ:ACRX) Coverage Initiated at StockNews.comMarch 17, 2023 | americanbankingnews.comAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Sees Large Increase in Short InterestMarch 20, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 14, 2023 | marketwatch.comAcelRx Pharmaceuticals Shares Rise Premarket on Dsuvia Sale >ACRXMarch 14, 2023 | msn.comAcelRx adds 16% on plans to divest pain therapyMarch 14, 2023 | finance.yahoo.comAcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora PharmaceuticalsFebruary 24, 2023 | thestreet.comHere's Why AcelRx Pharmaceuticals (ACRX) Stock Gained TodayJanuary 18, 2023 | forbes.comAcelrx PharmaceuticalsMarch 20, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.December 29, 2022 | finance.yahoo.comAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call TranscriptDecember 27, 2022 | finance.yahoo.comAcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common StockDecember 26, 2022 | benzinga.comLooking Into AcelRx Pharmaceuticals's Return On Capital EmployedDecember 8, 2022 | finance.yahoo.comAcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical MedicineNovember 17, 2022 | finance.yahoo.comAcelRx Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 15, 2022 | markets.businessinsider.comAcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 3, 2022 | finance.yahoo.comAcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022October 31, 2022 | finance.yahoo.comAcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022October 27, 2022 | finance.yahoo.comAcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, AguettantOctober 26, 2022 | finanznachrichten.deAcelRx Pharmaceuticals, Inc.: AcelRx Pharmaceuticals Announces Reverse Stock SplitOctober 26, 2022 | finance.yahoo.comAcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022October 25, 2022 | msn.comAcelRx Pharmaceuticals Announces 20-For-1 Reverse Stock Split Effective Tomorrow, Oct. 26October 25, 2022 | finance.yahoo.comAcelRx Pharmaceuticals Announces Reverse Stock SplitOctober 25, 2022 | finance.yahoo.comAcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health SciencesSeptember 23, 2022 | seekingalpha.comACRX AcelRx Pharmaceuticals, Inc.September 6, 2022 | msn.comAcelRx Pharmaceuticals's Return On Capital Employed OverviewAugust 25, 2022 | finance.yahoo.comAcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual MeetingAugust 18, 2022 | seekingalpha.comAcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors WellSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRX Company Calendar Last Earnings11/15/2021Today3/20/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACRX CUSIPN/A CIK1427925 Webwww.acelrx.com Phone(650) 216-3500Fax650-216-6500Employees43Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$6.26 Trailing P/E Ratio0.11 Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,100,000.00 Net Margins3,111.24% Pretax Margin3,112.16% Return on EquityN/A Return on Assets-50.06% Debt Debt-to-Equity RatioN/A Current Ratio1.57 Quick Ratio1.51 Sales & Book Value Annual Sales$2.82 million Price / Sales1.74 Cash FlowN/A Price / Cash FlowN/A Book Value($6.02) per share Price / Book-0.11Miscellaneous Outstanding Shares7,450,000Free Float7,032,000Market Cap$4.92 million OptionableOptionable Beta0.27 Key ExecutivesVincent J. AngottiPresident, Chief Executive Officer & DirectorRaffi AsadorianChief Financial & Accounting OfficerPamela Pierce PalmerDirector & Chief Medical OfficerBadri N. DasuChief Engineering OfficerMark A. EvashenkVice President-Clinical OperationsKey CompetitorsVallon PharmaceuticalsNASDAQ:VLONPainReformNASDAQ:PRFXExicureNASDAQ:XCURKintara TherapeuticsNASDAQ:KTRACohBarNASDAQ:CWBRView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 367,102 shares on 2/15/2023Ownership: 4.928%Tang Capital Management LLCSold 193,468 shares on 2/15/2023Ownership: 2.618%Susquehanna International Group LLPBought 63,554 shares on 2/14/2023Ownership: 0.853%Geode Capital Management LLCSold 1,102,050 shares on 2/13/2023Ownership: 0.806%Texas Capital Bank Wealth Management Services Inc.Sold 408,500 shares on 2/9/2023Ownership: 0.289%View All Insider TransactionsView All Institutional Transactions ACRX Stock - Frequently Asked Questions How have ACRX shares performed in 2023? AcelRx Pharmaceuticals' stock was trading at $2.26 at the beginning of 2023. Since then, ACRX stock has decreased by 70.8% and is now trading at $0.66. View the best growth stocks for 2023 here. Are investors shorting AcelRx Pharmaceuticals? AcelRx Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 666,600 shares, an increase of 7.9% from the February 13th total of 617,600 shares. Based on an average daily volume of 156,700 shares, the days-to-cover ratio is currently 4.3 days. Approximately 8.3% of the shares of the company are short sold. View AcelRx Pharmaceuticals' Short Interest. When is AcelRx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our ACRX earnings forecast. How were AcelRx Pharmaceuticals' earnings last quarter? AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its quarterly earnings results on Monday, November, 15th. The specialty pharmaceutical company reported ($1.40) EPS for the quarter, meeting analysts' consensus estimates of ($1.40). The specialty pharmaceutical company had revenue of $1.86 million for the quarter, compared to the consensus estimate of $1.20 million. During the same period in the prior year, the business posted ($2.00) earnings per share. When did AcelRx Pharmaceuticals' stock split? AcelRx Pharmaceuticals's stock reverse split on the morning of Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of AcelRx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA). What is AcelRx Pharmaceuticals' stock symbol? AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX." Who are AcelRx Pharmaceuticals' major shareholders? AcelRx Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (4.93%), Tang Capital Management LLC (2.62%), Susquehanna International Group LLP (0.85%), Geode Capital Management LLC (0.81%), Values First Advisors Inc. (0.50%) and Texas Capital Bank Wealth Management Services Inc. (0.29%). Insiders that own company stock include Adrian Adams and Vincent J Angotti. View institutional ownership trends. How do I buy shares of AcelRx Pharmaceuticals? Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AcelRx Pharmaceuticals' stock price today? One share of ACRX stock can currently be purchased for approximately $0.66. How much money does AcelRx Pharmaceuticals make? AcelRx Pharmaceuticals (NASDAQ:ACRX) has a market capitalization of $4.92 million and generates $2.82 million in revenue each year. The specialty pharmaceutical company earns $-35,100,000.00 in net income (profit) each year or $6.26 on an earnings per share basis. How can I contact AcelRx Pharmaceuticals? AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.acelrx.com. The specialty pharmaceutical company can be reached via phone at (650) 216-3500, via email at bkorb@troutgroup.com, or via fax at 650-216-6500. This page (NASDAQ:ACRX) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.